Risk Assessment of the Public Health Impact From Foodborne Listeria monocytogenes, 3617-3619 [E9-938]
Download as PDF
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 74, No. 12 / Wednesday, January 21, 2009 / Notices
modeled in our risk and benefit analysis
was modest. When we modeled actual
baseline consumption for the range of
methylmercury concentrations (low to
high) the assessment indicated a
significant probability of a net adverse
effect for 1/10 of 1 percent of children
for the central estimate. The highest
estimated net adverse effect was also
quite modest. For fatal coronary heart
disease and stroke, commercial fish
baseline consumption is averting a
central estimate of over 30,000 deaths
per year from coronary heart disease
and over 20,000 deaths per year from
stroke. The results of our quantitative
risk and benefit assessment are
generally consistent with research
reported in recent years in the scientific
literature.
The draft summary of published
research identifies primarily secondary
analyses of the large body of scientific
research on the impact of fish and
omega-3 fatty acids on cardiovascular
and neurologic endpoints, including
research on both prenatal and post-natal
exposures. In addition to the IOM
report, these secondary analyses include
reports by the American Heart
Association, the European Food Safety
Authority, the International Society for
the Study of Fatty Acids and Lipids, the
World Health Organization and a
previous investigation by FDA. This
compendium of research was developed
by FDA for use in developing its
quantitative risk benefit assessment and
provides background for that document.
The draft summary of published
research identifies and delineates the
lines of scientific evidence that indicate
the association of fish and omega-3 fatty
acid consumption with cardiovascular
and neurodevelopmental health
outcomes. When available, the
compendium of research also identifies
reports of quantitative dose-response
relationships which may be relevant for
risk and benefit assessment modeling.
The draft summary of published
research describes the context of the
overall body of scientific evidence
currently available for potential
application to the risk and benefit
assessment modeling and the draft risk
and benefit assessment report.
The agency designated the draft risk
and benefit assessment report and the
draft summary of published research as
a ‘‘highly influential scientific
assessment’’ under the Office of
Management and Budget’s (OMB) Final
Information Quality Bulletin for Peer
Review (the Bulletin) (70 FR 2664,
January 14, 2005). In August 2008, FDA
submitted a draft of the risk and benefit
assessment report (which at the time
also incorporated the draft summary of
VerDate Nov<24>2008
18:54 Jan 16, 2009
Jkt 217001
published research) to seven scientific
experts outside the Federal Government,
from a range of scientific disciplines, for
purposes of obtaining each expert’s
independent, written peer review. The
draft risk and benefit assessment report
and the draft summary of published
research that are being made available
for public comment reflect revisions
made to date in response to the peer
reviewers’ comments and suggestions.
The Information Quality Act Bulletin for
Peer Review requires FDA to post at its
Web site a report of the peer review that:
(1) Contains the names and credentials
of the peer reviewers; (2) sets forth the
‘‘charge,’’ i.e., the scientific questions
asked of the reviewers; (3) provides the
verbatim comments submitted by each
reviewer (without attribution); and (4)
discusses what FDA has done to the
documents in response to the peer
reviewers’ comments. We have posted at
our Web site an interim draft of this
report that provides this information at
https://www.cfsan.fda.gov/~dms/
mehg109.html, although we expect and
plan to finalize this report after revising
our draft risk and benefit assessment
report and the draft summary of
published research, in response to
further expert and peer review
comments.
Separately, FDA solicited and
received comments from scientists at
other Federal agencies, including EPA,
the National Institutes of Health, the
Centers for Disease Control and
Prevention, and the National Oceanic
and Atmospheric Administration during
a review coordinated by OMB. The draft
risk and benefit assessment report and
the draft summary of published research
being made available for comment have
been revised to reflect revisions made in
response to the inter-agency reviewers’
comments.
At the same time we are making these
draft documents available for public
comment, we plan to provide a revised
draft to the original peer reviewers to
enable them to submit any further
comments. We will revise the draft risk
and benefit assessment report and the
draft summary of published research as
necessary after considering the public
comments and any additional comments
from the independent peer reviewers.
We also plan to provide the revised
version of the documents, a summary of
the public comments that address
significant scientific issues, and the
external peer review report to an FDA
scientific advisory committee.
After public and advisory committee
review of these documents are
complete, appropriate risk management
actions will then be considered on the
basis of currently available scientific
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
3617
information. The release of these
documents for public comment and peer
review do not in any way modify the
recommendations set forth in the 2004
advisory on fish consumption.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
The draft documents described in this
notice are available electronically at
https://cfsan.fda.gov/~dms/
mehg109.html.
IV. Access to Related Documents
All references listed in the reports are
available in FDA’s Division of Dockets
Management (see ADDRESSES). Computer
programs used in the risk and benefit
assessment modeling are available from
Clark Carrington, Center for Food Safety
and Applied Nutrition (HFS–301), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740–
3835, 301–436–1947, e-mail:
Clark.Carrington@fda.hhs.gov.
Dated: January 14, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–1081 Filed 1–15–09; 11:15 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0658]
Risk Assessment of the Public Health
Impact From Foodborne Listeria
monocytogenes in Some Ready-to-Eat
Foods Sliced, Prepared, and/or
Packaged in Retail Facilities; Request
for Comments and for Scientific Data
and Information
AGENCY:
Food and Drug Administration,
HHS.
ACTION: Notice; request for comments
and for scientific data and information.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
E:\FR\FM\21JAN1.SGM
21JAN1
3618
Federal Register / Vol. 74, No. 12 / Wednesday, January 21, 2009 / Notices
mstockstill on PROD1PC66 with NOTICES
comments and scientific data and
information that would assist the agency
in its plans to conduct a risk assessment
of the public health impact of foodborne
Listeria monocytogenes in some readyto-eat foods sliced, prepared, and/or
packaged in retail facilities. The
purpose of the risk assessment is to
ascertain the impact on public health of
current practices and potential
interventions that reduce or prevent L.
monocytogenes contamination in readyto-eat food.
DATES: Submit comments and scientific
data and information by April 21, 2009.
ADDRESSES: Submit written comments
and scientific data and information to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments, scientific data,
and information to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Sherri Dennis, Center for Food Safety
and Applied Nutrition (HFS–005), Food
and Drug Administration, 5100 Paint
Branch Pkwy, College Park, MD 20740,
301–436–2355, e-mail:
sherri.dennis@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The Department of Health and Human
Services’ Healthy People 2010 is a
comprehensive set of disease prevention
and health promotion objectives for the
Nation to achieve over the first decade
of the new century. Created by scientists
both inside and outside of government,
it identifies a wide range of public
health priorities and specific,
measurable objectives. One of these
objectives calls on Federal food safety
agencies to reduce foodborne listeriosis
(Ref. 1). In support of this goal, in 2003,
FDA and the Food Safety and Inspection
Service (FSIS) of the U.S. Department of
Agriculture (USDA) issued an
assessment of the relative risk to public
health from foodborne Listeria
monocytogenes among selected
categories of ready-to-eat (RTE) foods
(Listeria risk assessment, Ref. 2). The
Listeria risk assessment formed the basis
of the 2003 FDA and Centers for Disease
Control and Prevention (CDC) Listeria
Action Plan (Ref. 3), which identifies
prevention and control activities that
FDA and CDC will take to reduce the
incidence of foodborne listeriosis in the
United States.
The 2003 Listeria risk assessment
provided the first quantitative estimate
of the relative risk of listeriosis from
consumption of a variety of RTE foods.
Among the RTE foods evaluated in the
VerDate Nov<24>2008
18:54 Jan 16, 2009
Jkt 217001
2003 risk assessment, deli meats (e.g.,
luncheon meats) were considered to
present the highest risk per serving and
the highest risk per annum. This rank
was the result of a moderate
contamination frequency, a high
number of servings consumed and high
growth rates of L. monocytogenes.
Additional data obtained in California
and Maryland showed that L.
monocytogenes prevalence and levels in
luncheon meats, deli-style salads, and
seafood salads were higher for in-storepackaged than for manufacturerpackaged foods (Ref. 4). This
observation was confirmed for meat and
poultry products in a study by the
National Alliance for Food Safety and
Security performed in northern
California, Georgia, Minnesota, and
Tennessee in 2008 (Ref. 5). Using these
latter results, it was estimated that most
of the listeriosis cases attributed to
ready-to-eat meat and poultry deli meats
are from products sliced and packaged
at retail (FSIS/USDA, unpublished
results).
Little is known about how Listeria
contamination occurs in retail facilities.
Retail practices may result in either
cross-contamination from one product
to another or through contamination
from the retail environment. There is
thus a need to identify potential sources
and practices that may increase L.
monocytogenes contamination in retail
settings and practices or interventions
that could reduce or eliminate L.
monocytogenes contamination of food
products (sold to consumers at the retail
level) and resulting human illness.
FDA is engaged in a risk assessment
that will evaluate the dynamics of L.
monocytogenes contamination in retail
facilities contributing to listeriosis. It
will evaluate how specific practices
could affect the overall level and
frequency of contamination, and the
relative effectiveness of various process
changes and intervention strategies
intended to reduce human illness. The
project will address FDA and USDA
regulated RTE foods. It will focus on
RTE foods that are sliced, prepared,
and/or packaged for the consumer in the
retail environment and consumed in the
home. Cheeses, deli meats, and delitype salads (as defined in Ref. 2) will be
studied as representative examples.
This risk assessment of the public
health impact of L. monocytogenes in
RTE foods sliced, prepared, and/or
packaged in retail facilities supports the
agency’s commitment to fulfilling the
Listeria Action Plan (Ref. 3).
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
II. Request for Comments and for
Scientific Data and Information
FDA requests comments on the risk
assessment goals outlined in this
document and the submission of
scientific data and information relevant
to the risk assessment. Specifically, we
request data and information about the
following:
1. Characteristics of ready-to-eat food
markets in the United States, including:
a. Volumes of cheeses and deli meats
sliced by manufacturers and the
volumes sliced in retail facilities,
b. Volumes of deli-type salads
prepared by manufacturers and the
volumes prepared in retail facilities, and
c. Volumes of ready-to-eat food sold
in delicatessen departments of major
grocery chains (i.e., large supermarket
facilities) and the volumes sold in other
groceries (i.e., multipurpose
independent small or local facilities).
2. Characteristics of deli departments
in groceries, including the proportion of
separated seafood/meat/dairy deli
departments in groceries.
3. Product contamination data,
including:
a. L. monocytogenes levels and/or
frequencies in wholesale products (deli
meats (chubs), cheeses, fresh produce,
seafood) arriving at retail facilities; and
b. L. monocytogenes levels and/or
frequencies in cheeses, deli meats, and
deli-type salads sold by retail facilities.
4. Factors that influence the growth of
L. monocytogenes in cheeses, deli
meats, and deli-type salads, including:
a. Growth rates of L. monocytogenes
in cheeses, deli meats, and deli-type
salads and the effects of different
ingredients in and compositions of
those products;
b. Chemical characteristics of cheeses,
deli meats, and deli-type salads that
could influence L. monocytogenes,
including pH and water activity;
c. Proportions of deli meats treated
with growth inhibitors, the inhibitors
used, the level of growth inhibitors, and
their efficiency;
d. Data on the temperatures to which
cheeses, deli meats, and deli-type salads
are exposed at retail, including time and
temperature for walk-in coolers or
refrigerators, display cabinets, and
ambient displays; and
e. Data on the use of advisory ‘‘useby’’ or ‘‘best by’’ labels for ready-to-eat
food sold by retail facilities.
5. Environmental contamination data,
including:
a. Data and information on the
prevalence and levels of L.
monocytogenes in the retail
environment including, e.g., drains,
countertops, walls, and equipment; and
E:\FR\FM\21JAN1.SGM
21JAN1
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 74, No. 12 / Wednesday, January 21, 2009 / Notices
b. Data on the growth of L.
monocytogenes on non-food surfaces
including environmental biofilm
growth.
6. Factors that influence the
environmental contamination and the
cross-contamination of food by L.
monocytogenes in retail facilities,
including:
a. Data and information on the
potential transfer of L. monocytogenes to
food from the retail environment, e.g.,
experimental studies on the transfer to
food from drains, slicers, food contact
surfaces, and non-food contact surfaces;
and
b. Data and information on food
handlers’ activities, e.g., observations of
food handlers’ practices and monitoring
of specific food safety actions in retail
facilities (e.g., glove usage, hand
hygiene practices, and cleaning
practices).
7. Identity and effectiveness of control
measures or interventions intended to
reduce levels and frequency of L.
monocytogenes in the retail
environment, including:
a. Environmental sanitation
procedures including the sanitizers and
protocols used, frequency of
application, and efficiency; and
b. Worker sanitation procedures
including frequencies, protocols, and
efficiency.
8. Any other data related to the
occurrence, growth, and control of L.
monocytogenes in retail facilities.
As the project progresses, additional
data needs may be identified.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that on January 15, 2008,
the FDA Division of Dockets
Management Web site transitioned to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. Electronic
comments or submissions will be
accepted by FDA only through FDMS at
https://www.regulations.gov.
III. References
The following references are on
display in the Division of Dockets
Management (see ADDRESSES) and may
VerDate Nov<24>2008
18:54 Jan 16, 2009
Jkt 217001
be seen by interested persons between 9
a.m. and 4 p.m., Monday through
Friday. (FDA has verified the Web site
addresses, but FDA is not responsible
for any subsequent changes to the Web
sites after this document publishes in
the Federal Register.)
1. U.S. Department of Health and Human
Services, Healthy People 2010, v. 1.
Washington, DC, 2000, https://
healthypeople.gov.
2. U.S. Department of Health and Human
Services and U.S. Department of Agriculture/
Food Safety and Inspection Service,
‘‘Quantitative Assessment of Relative Risk to
Public Health from Foodborne Listeria
monocytogenes Among Selected Categories
of Ready-to-Eat Foods,’’ September 2003,
https://www.foodsafety.gov/~dms/lmr2toc.html.
3. U.S. Department of Health and Human
Services, Food and Drug Administration/
Centers for Disease Control and Prevention,
‘‘Reducing the Risk of Listeria
monocytogenes FDA/CDC 2003 Update of the
Listeria Action Plan,’’ November 2003, https://
www.cfsan.fda.gov/~dms/lmr2plan.html.
4. Gombas, D.E., Chen, Y., Clavero, R.S.,
and Scott, V.N. (2003). Survey of Listeria
monocytogenes in ready-to-eat foods. Journal
of Food Protection, 66(4), 559–569.
5. Draughon, A.F. (2006). A collaborative
analysis/risk assessment of Listeria
monocytogenes in ready-to-eat processed
meat and poultry collected in four FoodNet
states. Symposium S–16: Contamination of
ready-to-eat foods: transfer and risk: Listeria
monocytogenes and other microorganisms.
International Association for Food Protection
93rd Annual Meeting, Calgary, Alberta.
August 13–16.
Dated: January 12, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–938 Filed 1–16–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Advisory Council on Migrant
Health; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: National Advisory Council on
Migrant Health.
Dates and Times: February 9, 2009, 8:30
a.m. to 5 p.m.; February 10, 2009, 8:30 a.m.
to 5 p.m.
Place: The Parklawn Building, Twinbrook
Room, 3rd Floor, 5600 Fishers Lane,
Rockville, Maryland 20857, Telephone: (301)
594–4303, Fax: (301) 443–0248.
Status: The meeting will be open to the
public.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
3619
Purpose: The purpose of the meeting is to
discuss services and issues related to the
health of migrant and seasonal farmworkers
and their families and to formulate
recommendations for the Secretary of Health
and Human Services.
Agenda: The agenda includes an overview
of the Council’s general business activities.
The Council will also hear presentations
from experts on farmworker issues, including
the status of farmworker health at the local
and national levels.
Agenda items are subject to change as
priorities indicate.
For Further Information Contact: Gladys
Cate, Office of Minority and Special
Populations, Bureau of Primary Health Care,
Health Resources and Services
Administration, 5600 Fishers Lane, Maryland
20857; telephone (301) 594–0367.
Wendy Ponton,
Director, Office of Management.
[FR Doc. E9–1067 Filed 1–16–09; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Mice With a Conditional LoxP-Flanked
Glucosylceramide Synthase Allele
Controlling Glycosphingolipid
Synthesis
Description of Technology:
Glycosphingolipids are organizational
building blocks of plasma membranes
that participate in key cellular
E:\FR\FM\21JAN1.SGM
21JAN1
Agencies
[Federal Register Volume 74, Number 12 (Wednesday, January 21, 2009)]
[Notices]
[Pages 3617-3619]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-938]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0658]
Risk Assessment of the Public Health Impact From Foodborne
Listeria monocytogenes in Some Ready-to-Eat Foods Sliced, Prepared,
and/or Packaged in Retail Facilities; Request for Comments and for
Scientific Data and Information
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments and for scientific data and
information.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
[[Page 3618]]
comments and scientific data and information that would assist the
agency in its plans to conduct a risk assessment of the public health
impact of foodborne Listeria monocytogenes in some ready-to-eat foods
sliced, prepared, and/or packaged in retail facilities. The purpose of
the risk assessment is to ascertain the impact on public health of
current practices and potential interventions that reduce or prevent L.
monocytogenes contamination in ready-to-eat food.
DATES: Submit comments and scientific data and information by April 21,
2009.
ADDRESSES: Submit written comments and scientific data and information
to the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments, scientific data, and information to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Sherri Dennis, Center for Food Safety
and Applied Nutrition (HFS-005), Food and Drug Administration, 5100
Paint Branch Pkwy, College Park, MD 20740, 301-436-2355, e-mail:
sherri.dennis@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The Department of Health and Human Services' Healthy People 2010 is
a comprehensive set of disease prevention and health promotion
objectives for the Nation to achieve over the first decade of the new
century. Created by scientists both inside and outside of government,
it identifies a wide range of public health priorities and specific,
measurable objectives. One of these objectives calls on Federal food
safety agencies to reduce foodborne listeriosis (Ref. 1). In support of
this goal, in 2003, FDA and the Food Safety and Inspection Service
(FSIS) of the U.S. Department of Agriculture (USDA) issued an
assessment of the relative risk to public health from foodborne
Listeria monocytogenes among selected categories of ready-to-eat (RTE)
foods (Listeria risk assessment, Ref. 2). The Listeria risk assessment
formed the basis of the 2003 FDA and Centers for Disease Control and
Prevention (CDC) Listeria Action Plan (Ref. 3), which identifies
prevention and control activities that FDA and CDC will take to reduce
the incidence of foodborne listeriosis in the United States.
The 2003 Listeria risk assessment provided the first quantitative
estimate of the relative risk of listeriosis from consumption of a
variety of RTE foods. Among the RTE foods evaluated in the 2003 risk
assessment, deli meats (e.g., luncheon meats) were considered to
present the highest risk per serving and the highest risk per annum.
This rank was the result of a moderate contamination frequency, a high
number of servings consumed and high growth rates of L. monocytogenes.
Additional data obtained in California and Maryland showed that L.
monocytogenes prevalence and levels in luncheon meats, deli-style
salads, and seafood salads were higher for in-store-packaged than for
manufacturer-packaged foods (Ref. 4). This observation was confirmed
for meat and poultry products in a study by the National Alliance for
Food Safety and Security performed in northern California, Georgia,
Minnesota, and Tennessee in 2008 (Ref. 5). Using these latter results,
it was estimated that most of the listeriosis cases attributed to
ready-to-eat meat and poultry deli meats are from products sliced and
packaged at retail (FSIS/USDA, unpublished results).
Little is known about how Listeria contamination occurs in retail
facilities. Retail practices may result in either cross-contamination
from one product to another or through contamination from the retail
environment. There is thus a need to identify potential sources and
practices that may increase L. monocytogenes contamination in retail
settings and practices or interventions that could reduce or eliminate
L. monocytogenes contamination of food products (sold to consumers at
the retail level) and resulting human illness.
FDA is engaged in a risk assessment that will evaluate the dynamics
of L. monocytogenes contamination in retail facilities contributing to
listeriosis. It will evaluate how specific practices could affect the
overall level and frequency of contamination, and the relative
effectiveness of various process changes and intervention strategies
intended to reduce human illness. The project will address FDA and USDA
regulated RTE foods. It will focus on RTE foods that are sliced,
prepared, and/or packaged for the consumer in the retail environment
and consumed in the home. Cheeses, deli meats, and deli-type salads (as
defined in Ref. 2) will be studied as representative examples.
This risk assessment of the public health impact of L.
monocytogenes in RTE foods sliced, prepared, and/or packaged in retail
facilities supports the agency's commitment to fulfilling the Listeria
Action Plan (Ref. 3).
II. Request for Comments and for Scientific Data and Information
FDA requests comments on the risk assessment goals outlined in this
document and the submission of scientific data and information relevant
to the risk assessment. Specifically, we request data and information
about the following:
1. Characteristics of ready-to-eat food markets in the United
States, including:
a. Volumes of cheeses and deli meats sliced by manufacturers and
the volumes sliced in retail facilities,
b. Volumes of deli-type salads prepared by manufacturers and the
volumes prepared in retail facilities, and
c. Volumes of ready-to-eat food sold in delicatessen departments of
major grocery chains (i.e., large supermarket facilities) and the
volumes sold in other groceries (i.e., multipurpose independent small
or local facilities).
2. Characteristics of deli departments in groceries, including the
proportion of separated seafood/meat/dairy deli departments in
groceries.
3. Product contamination data, including:
a. L. monocytogenes levels and/or frequencies in wholesale products
(deli meats (chubs), cheeses, fresh produce, seafood) arriving at
retail facilities; and
b. L. monocytogenes levels and/or frequencies in cheeses, deli
meats, and deli-type salads sold by retail facilities.
4. Factors that influence the growth of L. monocytogenes in
cheeses, deli meats, and deli-type salads, including:
a. Growth rates of L. monocytogenes in cheeses, deli meats, and
deli-type salads and the effects of different ingredients in and
compositions of those products;
b. Chemical characteristics of cheeses, deli meats, and deli-type
salads that could influence L. monocytogenes, including pH and water
activity;
c. Proportions of deli meats treated with growth inhibitors, the
inhibitors used, the level of growth inhibitors, and their efficiency;
d. Data on the temperatures to which cheeses, deli meats, and deli-
type salads are exposed at retail, including time and temperature for
walk-in coolers or refrigerators, display cabinets, and ambient
displays; and
e. Data on the use of advisory ``use-by'' or ``best by'' labels for
ready-to-eat food sold by retail facilities.
5. Environmental contamination data, including:
a. Data and information on the prevalence and levels of L.
monocytogenes in the retail environment including, e.g., drains,
countertops, walls, and equipment; and
[[Page 3619]]
b. Data on the growth of L. monocytogenes on non-food surfaces
including environmental biofilm growth.
6. Factors that influence the environmental contamination and the
cross-contamination of food by L. monocytogenes in retail facilities,
including:
a. Data and information on the potential transfer of L.
monocytogenes to food from the retail environment, e.g., experimental
studies on the transfer to food from drains, slicers, food contact
surfaces, and non-food contact surfaces; and
b. Data and information on food handlers' activities, e.g.,
observations of food handlers' practices and monitoring of specific
food safety actions in retail facilities (e.g., glove usage, hand
hygiene practices, and cleaning practices).
7. Identity and effectiveness of control measures or interventions
intended to reduce levels and frequency of L. monocytogenes in the
retail environment, including:
a. Environmental sanitation procedures including the sanitizers and
protocols used, frequency of application, and efficiency; and
b. Worker sanitation procedures including frequencies, protocols,
and efficiency.
8. Any other data related to the occurrence, growth, and control of
L. monocytogenes in retail facilities.
As the project progresses, additional data needs may be identified.
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at https://www.regulations.gov.
III. References
The following references are on display in the Division of Dockets
Management (see ADDRESSES) and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday through Friday. (FDA has verified the
Web site addresses, but FDA is not responsible for any subsequent
changes to the Web sites after this document publishes in the Federal
Register.)
1. U.S. Department of Health and Human Services, Healthy People
2010, v. 1. Washington, DC, 2000, https://healthypeople.gov.
2. U.S. Department of Health and Human Services and U.S.
Department of Agriculture/ Food Safety and Inspection Service,
``Quantitative Assessment of Relative Risk to Public Health from
Foodborne Listeria monocytogenes Among Selected Categories of Ready-
to-Eat Foods,'' September 2003, https://www.foodsafety.gov/~dms/lmr2-
toc.html.
3. U.S. Department of Health and Human Services, Food and Drug
Administration/Centers for Disease Control and Prevention,
``Reducing the Risk of Listeria monocytogenes FDA/CDC 2003 Update of
the Listeria Action Plan,'' November 2003, https://www.cfsan.fda.gov/
~dms/lmr2plan.html.
4. Gombas, D.E., Chen, Y., Clavero, R.S., and Scott, V.N.
(2003). Survey of Listeria monocytogenes in ready-to-eat foods.
Journal of Food Protection, 66(4), 559-569.
5. Draughon, A.F. (2006). A collaborative analysis/risk
assessment of Listeria monocytogenes in ready-to-eat processed meat
and poultry collected in four FoodNet states. Symposium S-16:
Contamination of ready-to-eat foods: transfer and risk: Listeria
monocytogenes and other microorganisms. International Association
for Food Protection 93rd Annual Meeting, Calgary, Alberta. August
13-16.
Dated: January 12, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-938 Filed 1-16-09; 8:45 am]
BILLING CODE 4160-01-S